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Neutrophil Defensins Enhance Lung Epithelial Wound Closure
and Mucin Gene Expression In Vitro
Jamil Aarbiou, Renate M. Verhoosel, Sandra van Wetering, Willem I. de Boer, J. Han J. M. van Krieken,
Sergey V. Litvinov, Klaus F. Rabe, and Pieter S. Hiemstra
Departments of Pulmonology and Pathology, Leiden University Medical Center, Leiden; and Department of Pathology,
University Medical Center St. Radboud, Nijmegen, The Netherlands
Human airways are frequently exposed to potentially harmful
agents that cause tissue injury. Upon such injury, a repair process
is initiated that comprises cell migration, proliferation, and differ-
entiation. We have previously shown that human neutrophil de-
fensins (human neutrophil peptides 1–3 [HNP1–3]) induce airway
epithelial cell proliferation. Because of the role of cell prolifera-
tion in epithelial wound repair, we investigated the effect of
HNP1–3 on airway epithelial wound closure and mucin gene
expression in vitro. Using NCI-H292 airway epithelial cell cultures,
we demonstrated that HNP1–3 cause a dose- and time-depen-
dent increase of wound closure as well as increased cell migration.
Furthermore, HNP1–3 caused a biphasic activation of the mitogen-
activated protein kinase extracellular-regulated kinase 1 and 2
(ERK1/2). Both the effects of HNP1–3 on wound closure and
ERK1/2 activation were blocked by specific inhibitors of the
mitogen-activated protein kinase kinase MEK, whereas inhibi-
tors of epidermal growth factor receptor tyrosine kinase, phos-
phatidylinositol 3-kinase, and Src did block defensin-enhanced
wound closure but not ERK1/2 activation. Finally, HNP1–3 in-
creased mRNA encoding the mucins MUC5B and MUC5AC, sug-
gesting a role for defensins in mucous cell differentiation. These
results indicate that neutrophil defensins increase epithelial
wound repair in vitro, which involves migration and prolifera-
tion, and mucin production. Neutrophil defensin–enhanced
wound repair appears to require epidermal growth factor re-
ceptor activation and downstream signaling pathways.
The integrity of the airway epithelium is an important pre-
requisite for an efficient host defense system. Epithelial
injury, as observed in various inflammatory lung diseases
(1), is followed by a repair process that serves to restore
epithelial integrity. During this repair process inflammatory
cells such as neutrophils are recruited to the site of injury,
and these cells may contribute to host defense, injury, and
the repair process itself (2–5). The functional effects of
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neutrophils during inflammation and subsequent wound re-
pair are dependent on the extent of their activation and
the products that are released. Neutrophil defensins consti-
tute one group of products released from stimulated neutro-
phils that kill microorganisms as well as host cells at the
site of inflammation, but recent data suggest that they may
also contribute to epithelial repair (6, 7).
Defensins are small, arginine-rich cationic peptides that
contain six highly conserved cysteine residues, forming a
compact looped structure. Depending on the positions of
the cysteine residues that participate in disulphide linkages,
defensins are divided in - and -defensin families (8). The
defensins that are released by stimulated neutrophils (called
human neutrophil peptides 1–4 [HNP1–4]) are members of
the -defensin subfamily that are stored in large amounts
in the azurophilic granules (9). Whereas they are mainly
present in neutrophils (hence the name neutrophil defen-
sins), their production has also been detected in certain
lymphocyte subsets (10). Neutrophil defensins, originally
identified as broad-spectrum antimicrobial peptides, have
more recently been implicated in the regulation of inflam-
matory and immunologic processes, including complement
activation; cytotoxicity; chemotaxis of immature dendritic
cells, T cells, and monocytes; induction of epithelial cyto-
kine release; and enhancement of humoral and cellular im-
mune responses (reviewed in Ref. 11). Finally, a possible
role of defensins in wound repair is suggested by results
from in vitro studies showing that neutrophil defensins en-
hance proliferation of human lung epithelial (7) and renal
carcinoma cells (12), and murine fibroblasts and retinal
epithelial cells (6).
Epithelial injury is normally followed by a complex re-
pair process that comprises subsequent epithelial migration,
proliferation, and differentiation (13). This process is medi-
ated predominantly via growth factors and their receptors,
including the epidermal growth factor (EGF) receptor that
plays a pivotal role in epithelial repair (14). Activation of
the EGF receptor is followed by stimulation of various
signaling pathways, including the mitogen-activated protein
kinases (MAPKs) p38, c-jun N-terminal kinase (JNK), extra-
cellular–regulated kinase 1 and 2 (ERK1/2), and big MAPK
(BMK, ERK5), that subsequently result in activation of vari-
ous transcription factors (e.g., activator protein-1 and nuclear
factor-B) and gene transcription. In particular, ERK1/2 and
ERK5 have been shown to be required for epithelial cell
growth (15).
Although neutrophil defensins display growth-promot-
ing activities toward cells of different origin, their role in
wound repair and the mechanism underlying this activity
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have not been clarified. The aim of this study was primarily
to delineate the role of neutrophil defensins in airway epi-
thelial wound repair by assessment of their effect on epithe-
lial wound closure. In addition, we determined the effect
of defensins on epithelial mucin gene expression, as mucin
expression is a feature associated with differentiation of
mucous epithelial cells. Furthermore, we aimed to unravel
the mechanism underlying these activities. Because of the
importance of EGF receptor signaling in epithelial wound
repair and the observation that neutrophil defensin–
mediated lung epithelial cell proliferation is inhibited by a
specific inhibitor of the ERK1/2 signaling pathway (7), we
focused on the involvement of this pathway.
Material and Methods
Defensin Isolation
Human neutrophil defensins were isolated from neutrophil granules
as a mixture of HNP-1, -2, and -3 as previously described (7, 16).
Cell Culture
Cells from the muco-epidermoid lung carcinoma cell line NCI-
H292 (ATCC, Manassas, VA) were cultured at 37C in a 5%
CO2-humidified atmosphere in RPMI 1640 medium (Gibco, Grand
Island, NY), supplemented with 2 mM L-glutamine, 20 U/ml peni-
cillin, 20 g/ml streptomycin (Bio Wittaker, Walkersville, MD),
and 10% heat-inactivated fetal calf serum (FCS; Gibco).
Subcultures of primary bronchial epithelial cells (PBEC) were
obtained from resected lung tissue, derived from patients that
underwent a pneumectomy or lobectomy for lung cancer at the
Leiden University Medical Center. Bronchial epithelial cells were
isolated essentially as previously described (17) using enzymatic
digestion with 0.1% (wt/vol) proteinase XIV (Sigma Aldrich,
St. Louis, MO). Epithelial cells were gently stripped, washed in
keratinocyte serum-free medium (Gibco), and incubated sub-
merged in keratinocyte serum-free medium, supplemented with
0.2 ng/ml EGF (Gibco), 25 g/ml bovine pituitary extract (Gibco),
1 M isoproterenol, 20 U/ml penicillin, 20 g/ml streptomycin,
and 10g/ml cyproxin (Bayer, Leverkusen, Germany). PBEC were
cultured in tissue culture plates precoated with 10g/ml fibronectin
(isolated from human plasma), 30g/ml Vitrogen (Cohesion Tech-
nologies Inc., Palo Alto, CA), and 10 g/ml bovine serum albumin
(Sigma Aldrich). For the experiments, cells from passage two were
cultured in Dulbecco’s modified Eagle’s medium/Ham’s F12 (1:1)
medium (Gibco) supplemented with 10 ng/ml EGF, 2% (vol/vol)
Ultroser G (Gibco), 1 M isoproterenol, 1 M insulin (Sigma
Aldrich), 1 M hydrocortisone (Sigma Aldrich), 2 mM L-gluta-
mine, 1 mM Hepes (Gibco), 20 U/ml penicillin, and 20 g/ml
streptomycin.
Wound Repair Model
NCI-H292 cells were cultured to confluence in 6-well tissue culture
plates. After overnight serum deprivation, three circular wounds
(3 mm in diameter) were scraped in each well using a sharpened
silicone tube attached to a Pasteur pipette and a microscope. After
washing with PBS and allowing the cultures to recover for 1 h in
serum-free medium, the wounded monolayers were incubated in
serum-free medium alone or supplemented with transforming
growth factor (TGF)- (Sigma Aldrich), HNP1–3, or FCS at con-
centrations as indicated. To study the role of selected signaling
pathways, wounded monolayers were incubated with AG1478
(1 M; Calbiochem, La Jolla, CA), PD98059 (50 M; Alexis,
Nottingham, UK), U0126 (25 M; Promega, Madison, WI),
LY294002 (10M; Stratagene, La Jolla, CA) or PP1 (25M; Alexis)
1 h before addition of HNP1–3 or TGF-. Possible cytotoxic effects
of the inhibitors at concentrations used in these experiments were
excluded by Trypan Blue assays (data not shown). Images were
collected using a digital camera and analyzed using Axiovision soft-
ware (Carl Zeiss Vision, Mu¨nchen-Hallbermoos, Germany) at vari-
ous time points by determining the percentage remaining wound
area as compared with the time point of stimulation (t  0).
Cell Migration Assay
Cell migration was assessed using a modified Boyden chamber
assay. NCI-H292 cells were cultured overnight in serum-free me-
dium and subsequently detached using 5 mM EDTA. Next, the
cells were added to the upper compartment of Transwell filters
(8 m pore-size; Costar, Cambridge, MA) in serum-free medium.
Following addition of medium alone or supplemented with 8 g/ml
HNP1–3 or 10% FCS to the lower, the upper, or both compart-
ments, the cells were allowed to migrate for 6 h. After removal
of the cells on the topside of the filters and fixation with 4%
paraformaldehyde for 20 min, cells were stained with hematoxylin
and migrated cells were counted in three high-power fields (400
magnification).
MAPK Activation Assays
For the detection of native and activated MAPKs in NCI-H292,
cells were cultured to 80–90% confluence. After overnight starva-
tion in serum-free RPMI medium, the cells were incubated with
HNP1–3, TGF- or tumor necrosis factor (TNF)- (PeproTech,
Rocky Hill, NJ) in serum-free medium. The effects of the various
inhibitors of the EGF receptor signaling pathway were assessed
by incubating NCI-H292 cells with these inhibitors using concen-
trations as described for wound closure experiments. In addition,
the involvement of ligand binding to the EGF receptor in ERK1/2
activation was evaluated by preincubating cells with 2g/ml mouse
monoclonal anti-EGF receptor antibodies (Ab-10; NeoMarkers,
Fremont, CA) for 1 h before addition of 8 g/ml HNP1–3 or
20 ng/ml TGF- and subsequent incubation for 15 min or 10 h.
For experiments with PBEC, cells were starved and subsequently
incubated with various stimuli in Dulbecco’s modified Eagle’s me-
dium/Ham’s F12 medium supplemented with 2 mM L-glutamine,
1 mM Hepes, 200 U/ml penicillin, and 200 g/ml streptomycin.
Next, the cells were washed and lysed with sample buffer (for p38
and JNK detection; 0.2 M Tris-HCl pH 6.8, 4% [wt/vol] SDS, 16%
[vol/vol] glycerol, 4% [vol/vol] 2-mercaptoethanol, 0.003% [wt/
vol] bromophenol blue), or lysis buffer (for ERK1/2 detection;
0.5% [vol/vol] Triton X-100, 0.1 M Tris-HCl pH 7.4, 100 mM NaCl,
1 mM MgCl2, 1 mM CaCl2, 1 mM Na3VO4, complete protease
inhibitor cocktail [Roche, Basel, Switzerland]) on ice. Eight to
fifteen micrograms total protein of each sample was separated on a
10% glycine-based gel using the Mini-protean 3 (Biorad, Hercules,
CA) SDS-PAGE system. Separated proteins were transferred to
polyvinylidene difluoride membranes using the Mini-transblot sys-
tem (Biorad) and used for detection of native and activated
MAPKs. Therefore, the membranes were pre-incubated with
0.05% Tween-20 in PBS (PBST) containing 0.5% (wt/vol) casein
or 5% (wt/vol) nonfat dry milk (ELK; Campina, Zoetermeer,
The Netherlands) for at least 1 h, followed by incubation with
anti–phospho-ERK1/2, -p38, or -JNK rabbit polyclonal antibodies
(all from New England Biolabs, Beverly, MA) overnight at 4C.
After incubation with horseradish peroxidase–conjugated goat
anti-rabbit (for ERK1/2; BD Transduction Laboratories, Franklin
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Lake, NJ) or donkey anti-rabbit (for p38 and JNK; Amersham
Pharmacia Biotech, Uppsala, Sweden) antibodies, immunoreactiv-
ity was visualized using electrochemiluminescent detection reagent
(Amersham). In selected experiments, the ratio of phosphorylated
and total ERK1/2 was determined by densitometry using Eagle
Eye software (Stratagene).
EGF Receptor Immunoprecipitation Assays
For the detection of phosphorylated EGF receptor, NCI-H292
cells were cultured to near confluence, serum-deprived overnight,
and subsequently incubated with medium alone or supplemented
with 8 g/ml HNP1–3 or 20 ng/ml TGF- for 15 min or 10 h. After
washing in ice-cold buffer (1 mM CaCl2, 1 mM MgCl2 in PBS),
the cells were lysed in ice-cold RIPA buffer (150 mM NaCl, 50
mM Tris pH 7.8, 1% [vol/vol] Triton-X 100, 50 mM NaF, 5 mM
PMSF, 1 mM Na3VO4, complete protease inhibitor cocktail) for
10 min. The EGF receptor was immunoprecipitated by incubating
the cell lysates with anti-EGF receptor monoclonal antibodies (BD
Transduction Laboratories) and subsequent binding to protein A
Sepharose 4 fast flow beads (Pharmacia Amersham) overnight at
4C. Immunoprecipitated native and phosphorylated EGF recep-
tor were detected by Western blot analysis, using anti-EGF recep-
tor monoclonal antibodies (BD Transduction Laboratories), or
horseradish peroxidase–conjugated anti-phosphotyrosine mono-
clonal antibodies (PY99; Santa Cruz Biotechnologies, Santa Cruz,
CA), respectively.
Cell Proliferation Assay
Cell proliferation was assessed by 5-bromo-2-deoxyuridin (BrdU)
incorporation. Confluent NCI-H292 cell monolayers were wounded
as described and incubated with various stimuli. Following addition
of 10 mM BrdU (Sigma Aldrich), the cells were incubated for a
further 24 h and fixed in 70% ethanol (vol/vol) for at least 1 h. BrdU
incorporation was assessed by immunocytochemistry as previously
described (7). BrdU-positive nuclei were enumerated within a dis-
tance of 10 cells from the wound edge and in intact areas. At least
300 nuclei were counted for each condition.
Reverse Transcriptase–Polymerase Chain Reaction
for MUC5B and MUC5AC
For analysis of mucin mRNA expression, PBEC and NCI-H292
cells were cultured and starved as described for Western blot
experiments. Following growth factor deprivation, cells were incu-
bated with medium alone or supplemented with 20 ng/ml TGF-, or
8 or 50 g/ml HNP1–3. RNA was extracted using TRIzol Reagent
(Gibco) and reverse transcribed using oligo(dT) primer and Molo-
ney murine leukemia virus reverse transcriptase (RT; Gibco) as
recommended by manufacturers. Equal loading of cDNA was eval-
uated using the housekeeping gene -actin. Amplification by poly-
merase chain reaction (PCR) was performed using primers for
-actin: 5-CTA CAA TGA GCT GCG TGT GG and 5-AAG
GAA GGC TGG AAG AGT GC; MUC5AC: 5-ATT TTT TCC
CCA CTC CTG ATG and 5-AAG ACA ACC CAC TCC CAA
CC; MUC5B: 5-CAC ATC CAC CCT TCC AAC and 5-GGC
TCA TTG TCG TCT CTG. PCR amplification was performed in a
final volume of 25 l PCR buffer (Eurogentech, Seraing, Belgium)
containing MgCl2 (2 mM for -actin, 2.5 mM for MUC5B and
MUC5AC), 1 M of each primer, 0.2 mM dNTP (Invitrogen,
Carlbad, CA) and 0.04 U/l Taq polymerase (Eurogentech). Am-
plified products were loaded on a 1% agarose gel.
Statistical Analysis
Results are expressed as mean 	 SEM. Data obtained from three
to four separate experiments were analyzed for statistical differ-
ence by the Student’s t test for paired samples and differences
were considered significant when P 
 0.05.
Results
Defensin-Enhanced Epithelial Wound Closure
To investigate the effects of neutrophil defensins on epithe-
lial wound closure, mechanically wounded NCI-H292 cell
monolayers were incubated with medium alone (negative
control) or with HNP1–3, TGF-, or FCS, and the wound
area was measured at various time points. Wounded mono-
layers incubated with 8g/ml HNP1–3 showed a slight delay
in wound closure in the first 18 h of incubation, followed
by a subsequent enhancement in wound closure resulting
in a significant increase after 48 and 72 h as compared with
monolayers incubated with medium alone (Figure 1A). In
Figure 1. Dose- and time-dependent enhancement of airway epi-
thelial wound closure by neutrophil defensins. Mechanically
wounded NCI-H292 monolayers were incubated with medium
alone (triangles) or supplemented with 8 g/ml HNP1–3 (squares),
20 ng/ml TGF- (circles), or 10% FCS (diamonds), and the percent-
age of closed wound area compared with t  0 h was measured
after 18, 24, 48, and 72 h (A ). (B) The time-dependent wound
closure at various HNP1–3 concentrations. Circles, t  18 h; trian-
gles, t 24 h; diamonds, t 48 h; squares, t 72 h. Data represent
mean 	 SEM of four separate experiments, each performed in
triplicate. *P 
 0.05 versus serum-free medium–treated cells.
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TGF-– and FCS-treated monolayers, 80–85% of the wound
area was closed after 48 h and 95–100% after 72 h. To
study the effect of HNP1–3 on wound closure, NCI-H292
cell monolayers were incubated with various HNP1–3 con-
centrations and residual wound area was determined at vari-
ous time points (Figure 1B). Maximal increase of wound
closure was observed at concentrations of 4–10 g/ml after
incubation for 48 or 72 h, whereas at a concentration of 50
g/ml wound closure was delayed.
Defensin-Induced MAPK Activation
To assess the involvement of MAPK signaling pathways in
defensin-enhanced epithelial repair, cell lysates prepared
from stimulated NCI-H292 cells were analyzed for activated
ERK1/2, p38, and JNK by Western blot analysis. In cell lysates
obtained from cells stimulated for 15 min with 8 g/ml
HNP1–3, 20 ng/ml TGF-, or 25 ng/ml TNF-, a marked
increase in activation of ERK1/2, p38, and JNK was ob-
served (Figure 2A). To study the kinetics of defensin-in-
duced ERK1/2 activation, NCI-H292 cells were stimulated
with 8 or 50 g/ml HNP1–3 or 20 ng/ml TGF- for various
time periods (Figure 2B). Like TGF-, HNP1–3 showed a
biphasic activation of ERK1/2. Both HNP1–3 concentra-
tions resulted in activation of ERK1/2 after 5 min which
persisted up to 1 h, whereas TGF- already resulted in
activation after 1 min that was maintained for 2 h. The
second activation phase was observed after 10 h of incuba-
tion with HNP1–3 and TGF-.
Activation of ERK1/2 by HNP1–3 was also analyzed in
PBEC (Figure 2C). The results showed that HNP1–3 and
TGF also induced activation of ERK1/2 in PBEC after
15 min.
Figure 2. (A ) Activation of MAPKs by neutrophil defensins. NCI-H292 cells were incubated with medium alone or supplemented with
8 g/ml HNP1–3, 20 ng/ml TGF-, or 25 ng/ml TNF- for 15 min. Phosphorylated ERK1/2 (pERK), JNK (pJNK), and p38 (p-p38) were
determined in cell lysates by Western blot. (B ) Biphasic activation of ERK1/2 by neutrophil defensins. NCI-H292 cells were incubated
with medium alone or supplemented with 20 ng/ml TGF-, 8 g/ml HNP1–3, or 50 g/ml HNP1–3 for the indicated time periods.
Phosphorylated and total ERK1/2 was determined in cell lysates by Western blot and the ratio (pERK/ERK) was determined by
densitometry. (C ) Activation of ERK1/2 in PBEC by neutrophil defensins. PBEC were incubated with medium alone or supplemented
with 20 ng/ml TGF-, 8 g/ml HNP1–3 (HNP 8), or 50 g/ml HNP1–3 (HNP 50) for 15 min and phosphorylated and total ERK was
determined. Data in A, B, and C are from one experiment (similar results were obtained in another separate experiment).
Involvement of EGF Receptor and MAPK Signaling in
Defensin-Induced ERK1/2 Activation
To further delineate the involvement of the EGF receptor
signaling pathway, NCI-H292 cells were incubated with in-
hibitors of EGF receptor tyrosine kinase (AG1478), MEK
(PD98059 and U0126), PI-3K (LY294002), and Src (PP1)
1 h before addition of HNP1–3 or TGF- for 15 min (Figure
3A). Western blot analysis of activated ERK1/2 demon-
strated that MEK inhibitors completely (U0126) or partially
(PD98059) blocked neutrophil defensin–induced ERK1/2
activation. Neutrophil defensin–induced ERK1/2 activation
was not blocked by AG1478, in contrast to activation in-
duced by TGF-. The PI-3K and Src inhibitors did not
affect neutrophil defensin– and TGF-–induced ERK1/2
activation, indicating that these kinases are not involved in
the signaling pathway leading to ERK1/2 activation.
Involvement of the EGF receptor in defensin-induced
ERK1/2 activation was also assessed by studying the effect
of blocking antibodies directed against the EGF receptor
on the activation of ERK1/2 (Figure 3B). These antibodies
did not affect the early phase (after 15 min) phosphorylation
of ERK1/2 induced by defensins, whereas they did block
the effect of TGF- at 2 ng/ml. These results are in line
with the results observed when using AG1478. In contrast to
what was observed at 15 min, late phase activation (after 10
h) by both defensins and TGF- was blocked by anti-EGF
receptor antibodies. In addition, we studied the effect of neu-
trophil defensins on EGF receptor activation (Figure 4).
No phosphorylation of the EGF receptor could be de-
tected after incubation with 8 g/ml HNP1–3 for 15 min,
whereas after 10 h of incubation a weak but reproducible
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Figure 3. (A ) Effect of inhibitors of the EGF receptor signaling
pathway on neutrophil defensin–induced ERK1/2 activation. NCI-
H292 cells were preincubated with AG1478 (AG; 1 M), PD98059
(PD; 50M), U0126 (U; 25 M), LY294002 (LY; 10 M), or PP1
(PP; 25 M) for 1 h before addition of 8 g/ml HNP1–3 (HNP)
or 20 ng/ml TGF- (TGF 20) for 15 min. (B ) Effect of EGF
receptor blocking antibodies on early and late phase ERK1/2 acti-
vation. NCI-H292 cells were preincubated with 2 g/ml anti-EGF
receptor antibodies (Ab) for 1 h before addition of 8 g/ml
HNP1–3 (HNP), 2 ng/ml TGF- (TGF 2), or 20 ng/ml TGF-
(TGF 20) for 15 min or 10 h. Phosphorylated (pERK1/2) and total
ERK1/2 was determined by Western blot. Data in A and B are
from one experiment (similar results were obtained in another
separate experiment).
phosphorylation was observed. Incubation with TGF-
resulted in a clear activation of the EGF receptor at both
time points.
Involvement of EGF Receptor and MAPK Signaling in
Defensin-Enhanced Wound Closure
To investigate whether the observed induction of epithelial
wound closure by neutrophil defensins is mediated via the
EGF receptor signaling pathway, the effect of the previously
described inhibitors on neutrophil defensin– and TGF-–
Figure 4. Effect of neutrophil defensins on EGF receptor activa-
tion. NCI-H292 cells were incubated with medium alone or supple-
mented with 20 ng/ml TGF-, 8 g/ml HNP1–3 (HNP 8), or 50
g/ml HNP1–3 (HNP 50) for 15 min or 10 h. After immunoprecipi-
tation of the EGF receptor, phosphorylated (pEGFR) and total
EGF receptor was detected by Western blot. Data are from one
experiment (similar results were obtained in another separate
experiment).
enhanced wound closure was assessed (Figure 5). All indi-
vidual inhibitors were shown to block the basal wound
closure. In line with the results on ERK1/2 activation,
PD98059 and U0126 significantly blocked both neutrophil
defensin– and TGF-–enhanced wound closure. Interest-
ingly, AG1478 completely blocked neutrophil defensin–
enhanced wound closure, although it did not affect ERK1/2
activation (Figure 3). PI-3K and Src have been implicated
in mediating cell migration and thereby may also contribute
to wound repair (18, 19). Inhibitors of these kinases signifi-
cantly blocked wound closure in neutrophil defensin– and
TGF-–stimulated cultures, suggesting that PI-3K and Src are
required for neutrophil defensin–enhanced wound closure.
Effect of Neutrophil Defensins on NCI-H292
Cell Migration
To examine the involvement of cell migration in defensin-
enhanced airway epithelial wound repair, the effect of neu-
trophil defensins on cell migration of NCI-H292 cells was
assessed (Table 1). Neutrophil defensins at 8 g/ml caused
a significant increase in cell migration as compared with
medium alone (34.1 	 2.8 versus 11.9 	 0.9 cells per high-
power field, respectively). Control stimulation with FCS
also resulted in a significant increase (27.9 	 2.6) in cell
migration. When these stimuli were added to the upper
compartment, or to both compartments, no increase in mi-
gration was observed. These results indicate that the activity
of HNP1–3 is chemotactic rather than chemokinetic.
BrdU Incorporation
Previous studies have demonstrated that neutrophil defen-
sins may induce proliferation of various cell types, including
human airway epithelial cells. We therefore used the wound
repair model in NCI-H292 cells to investigate the effect of
neutrophil defensins on proliferation of cells located within
the wounded area after (partial) wound closure, and of cells
in intact epithelial layers (Table 2). In all cultures, cell
proliferation was higher in epithelial cells present in the
original wound area as compared with cells in noninjured
areas of the same culture. HNP1–3, FCS, and TGF- stimu-
lated proliferation of epithelial cells; however, this was not
observed in the first 24 h in the wound area, and also not
in the last 24 h (48–72 h) in intact areas.
Mucin mRNA Expression
Effects of neutrophil defensins on mucin mRNA expression
were examined in PBEC and NCI-H292 cells (Figure 6). In
NCI-H292 cells, increased MUC5B and MUC5AC mRNA
expression was observed with 8g/ml HNP1–3 already after
5 h, that was maintained up to 24 h (MUC5AC) or 48 h
(MUC5B). Higher HNP1–3 concentrations (50 g/ml) did
not affect MUC5B in NCI-H292 cells, whereas TGF- in-
creased expression of MUC5B only after 24 h. PBEC incu-
bated with 8 or 50 g/ml HNP1–3 showed an increase in
MUC5B and MUC5AC mRNA expression already after
5 h, and this was maintained up to 48 h. Cells that were
incubated with TGF- showed an increase in MUC5B
mRNA expression after 24 h, but not after 5 or 48 h. Ele-
vated MUC5AC mRNA in PBEC with TGF- was ob-
served after stimulation for 5 or 24 h.
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Figure 5. Effect of inhibitors of the EGF receptor signaling pathway on neutrophil defensin–induced wound closure of NCI-H292
monolayers. Mechanically wounded NCI-H292 cell monolayers were preincubated with AG1478 (1 M), PD98059 (50M), U0126
(25 M), LY294002 (10 M), or PP1 (25 M) 1 h before addition of 8 g/ml HNP1–3 or 20 ng/ml TGF-. Data are mean 	 SEM of
three separate experiments. Closed triangles, medium; closed circles, TGF-; closed squares, HNP1–3; open triangles, inhibitor; open
circles, inhibitor  TGF-; open squares, inhibitor  HNP1–3.
Discussion
The results demonstrate that neutrophil defensins induce a
dose- and time-dependent enhancement of airway epithelial
wound closure. In addition, neutrophil defensins were shown
to cause activation of ERK1/2, p38, JNK, and the EGF recep-
tor. Inhibitors of the MAPK kinase MEK blocked defensin-
induced ERK1/2 activation, whereas EGF receptor–blocking
antibodies only inhibited late phase activation of ERK1/2.
The involvement of these signaling molecules in defensin-
enhanced wound closure was demonstrated by the blocking
effect of inhibitors of MEK and EGF receptor tyrosine kinase
on this process. The enhancement of wound closure by neu-
trophil defensins involved cell migration and cell prolifera-
tion. Finally, neutrophil defensins increase airway epithelial
mucin expression, as shown by mRNA expression of the
mucins MUC5B and MUC5AC.
TABLE 1
Neutrophil defensins enhance NCI-H292 cell migration
Upper Compartment
Lower Compartment Medium HNP1–3 FCS
Medium 11.9 	 0.9 11.8	 1.1† 9.9 	 0.8
HNP1–3 34.1 	 2.8* 9.7	 2.3† 9.3 	 0.5
FCS 27.9 	 2.6* 12.5	 0.7 9.8 	 0.8
Definition of abbreviations: FCS, fetal calf serum; HNP, human neutrophil
peptide.
NCI-H292 cell migration was assessed by modified Boyden chamber assays
after addition of medium alone or supplemented with 8 g/ml HNP1-3 or 10%
FCS to the lower, upper, or both compartments. Data are expressed as mean
number of migrated cells per high-power field 	 SEM of three independent
experiments.
* P 
 0.05 versus serum-free medium in both compartments.
† P
 0.01 versus serum-free medium in upper and HNP1-3 in lower compartment.
In previous studies, we and others demonstrated that
neutrophil defensins induce proliferation of human airway
epithelial (7) and renal carcinoma cells (12) and murine
fibroblasts and retinal epithelial cells (6), possibly allowing
neutrophil defensins to play a role in tissue repair. The
tissue repair process is complex and requires migration of
cells surrounding the injury before cell proliferation and
differentiation (13). Using mechanically wounded NCI-
H292 cell monolayers, we demonstrated that neutrophil
defensins enhance wound closure at the same range of con-
centrations that were described to enhance airway epithelial
cell proliferation (7). Addition of higher concentrations
( 50 g/ml) resulted in a delay of wound closure. This
delay is most likely due to cytotoxic effects of neutrophil
defensins and is in line with previous studies showing that
neutrophil defensins induce cytotoxicity in airway epithelial
cells at these concentrations (20). The effects of neutrophil
defensins on wound closure were time-dependent, and max-
imal closure rate was observed in the time period between
24 and 72 h. Interestingly, the rate of wound closure in the
early phase (first 18 h) after addition of neutrophil defensins
was lower than that observed with TGF-. This may be
due to an indirect effect of defensins on EGF receptor
activation, and is in line with the observed activation of the
EGF receptor at a later phase (10 h), but not in the early
phase (15 min).
Various studies have shown that growth factors and their
receptors play a pivotal role in airway epithelial repair pro-
cesses. Amongst these growth factor receptors, the EGF
receptor has been shown to modulate epithelial cell migration
and proliferation (13). Upon activation of this receptor by
its ligands (e.g., EGF, TGF-), various signaling pathways
are activated, such as the MAPK ERK1/2, p38, and JNK
signaling pathways. Although the latter two MAPKs may be
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TABLE 2
Induction of cell proliferation in wounded NCI-H292 cell monolayers
% BrdU-Positive Nuclei*
BrdU Incubation Period
0–24 h 24–48 h 48–72 h
Stimuli Wound Intact Wound Intact Wound Intact
Medium 17.5 	 1.7 9.3 	 1.9 24.6 	 0.8 17.0 	 1.8 28.3 	 4.2 21.1 	 5.1
FCS 24.7 	 5.6 29.6 	 3.3† 70.5 	 3.0† 57.6 	 5.5† 61.8 	 1.2† 15.1 	 3.1
HNP1–3 19.8 	 0.3 21.1 	 2.2 59.9 	 3.6† 54.7 	 6.4† 43.4 	 4.0 27.5 	 9.0
TGF- 10.7 	 1.7 12.8 	 2.8 54.4 	 0.8† 32.6 	 1.1† 31.6 	 0.4 16.5 	 2.3
Definition of abbreviations: FCS, fetal calf serum; HNP, human neutrophil peptide; TGF-, transforming growth factor-.
* Percentage BrdU-positive nuclei within a distance of 10 cells from the wound edge (i.e., within the original wound area) and in intact areas. Data are mean 	
SEM of three independent experiments.
† P 
 0.05 versus serum-free medium-treated cells.
activated by growth factors, in general they are activated by
stress-induced signals. The functional consequence of their
activation may vary depending on the stimulus and the cell
type, and may comprise induction of inflammatory cytokines
(21), growth arrest, and apoptosis (22). The ERK1/2 signal-
ing pathway is considered to be the most important in the
induction of epithelial cell growth (23, 24). This pathway
involves the subsequent activation of Ras, Raf, MEK1/2,
and ERK1/2. Activated ERK1/2 are then translocated to the
nucleus, where they activate various transcription factors,
resulting in transcription of various genes involved in cell
growth. The importance of this pathway in epithelial cell
growth, and the observation that the MEK inhibitor U0126
blocked defensin-induced airway epithelial cell prolifera-
tion (7), suggests a role for ERK1/2 signaling in defensin-
induced airway epithelial wound closure. Time-kinetics
experiments showed a biphasic activation of ERK1/2 in NCI-
Figure 6. Induction of MUC5B and MUC5AC mRNA expression
in NCI-H292 cells and PBEC by neutrophil defensins. Cells were
cultured in medium alone, or supplemented with 20 ng/ml TGF-,
8 g/ml HNP1–3 (HNP 8), or 50 g/ml HNP1–3 (HNP 50) for 5,
24, or 48 h. At these time points, RNA was isolated and mRNA
expression of MUC5B, MUC5AC, and -actin was determined by
RT-PCR. Data are from one experiment (similar results were
obtained in another separate experiment).
H292 cells: an early activation occurred already after 5 min
and persisted for approximately 1 h, and a late activation
phase after 10 h. This biphasic activation of ERK1/2 is compa-
rable to that observed with TGF- and has also been de-
scribed in vascular smooth muscle cells (25) and hepatocytes
(26) stimulated with cytokines or growth factors. In previous
studies performed in hamster fibroblasts it was demonstrated
that thrombin, which caused an early- and a late-phase activa-
tion of ERK1/2, was able to induce cell proliferation, whereas
substances (e.g., serotonin, carbachol) that only induced an
early phase activation did not (27, 28). These studies suggest
that the observed late phase activation of ERK1/2 may be
involved in the enhancement of wound closure by neutrophil
defensins. This is further supported by the observation that
neutrophil defensins fail to enhance EGF receptor activation
in the early phase although they do induce late phase activa-
tion. Specific inhibitors of the ERK1/2 signaling pathway
blocked defensin-induced ERK1/2 activation and wound clo-
sure, confirming the requirement of this pathway for neutro-
phil defensin–enhanced wound closure. These inhibitors also
blocked basal wound closure of NCI-H292 monolayers incu-
bated with medium alone. This is probably the result of
release of endogenous EGF receptor ligands by the epithelial
cells surrounding the wound area, as previously demonstrated
in a scrape wounding model (14). Interestingly, the EGF
receptor tyrosine kinase inhibitor AG1478 did not affect
defensin-induced ERK1/2 activation, although it did block
defensin-enhanced wound closure. A possible explanation
for this discrepancy may be that neutrophil defensins induce
EGF receptor–independent ERK1/2 activation, which may
subsequently lead to EGF receptor activation and wound
closure. This is possibly mediated by defensin-induced shed-
ding of growth factors, because shedding of the EGF receptor
ligands TGF- and HB-EGF has been shown to be regulated
via ERK1/2 and other MAPKs (29, 30). The possible indirect
activation of the EGF receptor via ERK1/2 activation is in
line with our observation that early ERK1/2 activation is
not inhibited by anti-EGF receptor antibodies, whereas late-
phase activation is. Our studies on EGF receptor and MAPK
phosphorylation were performed using near-confluent cul-
tures, in which spontaneous release of EGF receptor ligands
is lower than in the wounded cultures (14). Therefore, in
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the wound closure assays defensins may act by increasing
wounding-induced EGF receptor phosphorylation. Despite
this difference, it should be noted that defensins increase cell
proliferation both in near-confluent cultures (7) and in cells
near the wound area (this study), indicating a similar response
to defensins.
Our data suggest that neutrophil defensin–enhanced
wound closure may require activation of the EGF receptor,
whereas the immediate ERK1/2 activation following addition
of defensins (this study) and defensin-induced cell prolifera-
tion (7) may be EGF receptor–independent. How neutrophil
defensins activate epithelial cells is not known. Human -
defensins have been shown to interact with dendritic cells
through the chemokine receptor CCR6 (31) and Toll-like
receptor-4 (32), whereas as yet unidentified G-protein–
coupled receptors may be involved in the chemotactic activity
of neutrophil defensins on T- and dendritic cells (33). The
potential involvement of G-protein–coupled receptors in de-
fensin-induced signaling as observed in the present study is
of particular interest, as these receptors have been shown to
transactivate the EGF receptor via metalloproteinase-medi-
ated shedding of growth factors (34). A recent study demon-
strated the involvement of another membrane protein in
the effects of defensins on cellular behavior. In this study,
neutrophil defensins were found to inhibit smooth muscle
contraction via binding to the low-density lipoprotein recep-
tor–related protein/2-macroglobulin receptor (35). At pres-
ent it is unknown whether defensins act as classical ligands
for cellular receptors, or as recently suggested (36) may medi-
ate their effects by a mechanism that is independent of a
ligand–receptor interaction. The nature of the membrane
structures involved in mediating the effects of neutrophil
defensins on epithelial cell activity, as observed in the present
study, remains to be established.
We have shown that neutrophil defensins induce a localized
increase in cell proliferation in wounded areas, confirming
the importance of cell proliferation in the defensin-enhanced
wound closure. Interestingly, cell proliferation was not in-
creased in the wounds in the first 24 h after stimulation with
HNP1–3, FCS, or TGF-, suggesting that migration of epithe-
lial cells is the predominant mechanism of wound closure in
the first phase of the process preceding cell proliferation. The
involvement of cell migration in defensin-enhanced wound
closure is further supported by the observation that neutrophil
defensins increase NCI-H292 cell migration by acting as a
chemoattractant for these cells. Two EGF receptor–mediated
signaling pathways, the ERK1/2 and PI-3K pathways, have
been shown to be implicated in cell migration (18). We as-
sessed a possible involvement of the PI-3K signaling pathway
in defensin-enhanced wound closure using specific PI-3K and
Src inhibitors, and demonstrated that these inhibitors block
defensin-enhanced wound closure. These results suggest that
the ability of neutrophil defensins to increase epithelial cell
migration and proliferation contributes to the observed in-
crease in airway epithelial wound closure, and that this re-
quires activation of PI-3K and ERK1/2 signaling pathways.
The final step in epithelial repair is cell differentiation.
A characteristic of differentiated airway epithelium is that
a subpopulation of the cells produce and secrete mucins
such as the glycoproteins MUC5B and MUC5AC. Our
studies show increased mRNA expression of MUC5B and
MUC5AC in neutrophil defensin–treated airway epithelial
cells. Whether this indeed indicates that defensins reconsti-
tute an area of epithelial injury with fully differentiated
epithelial cells remains to be determined, because demon-
strating an increase in mucin mRNA does not suffice to
conclude that neutrophil defensins cause Goblet cell differ-
entiation. Other neutrophil products have been previously
shown to increase epithelial mucin expression. Takeyama and
coworkers (4, 37) demonstrated that MUC5AC expression
induced by oxidants or neutrophil supernatants in NCI-H292
cells is EGF receptor–dependent and antioxidant-sensitive.
In addition, Fisher and colleagues (38) demonstrated that
neutrophil elastase, a serine proteinase also stored in azuro-
philic granules, induces MUC5AC gene expression in A549
cells via an oxidant-dependent pathway. Although enhance-
ment of mucin expression may contribute to a more efficient
clearance of microorganisms, mucus hypersecretion may also
lead to airway obstruction. Therefore, excessive stimulation
of mucin expression by defensins may lead to mucus hyperse-
cretion, a feature of neutrophil-dominated inflammatory dis-
eases such as chronic bronchitis (39).
In summary, we demonstrated that neutrophil defensins
enhance airway epithelial wound closure in vitro, possibly
by inducing cell migration and proliferation. Furthermore,
we have shown that this enhancement requires both EGF
receptor and ERK1/2 activation. Neutrophil defensins were
also found to increase mucin gene expression. These data
suggest a pivotal role for neutrophil defensins in airway
epithelial wound repair. Whether defensins enhance wound
repair in vivo remains to be determined.
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